TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20459012

Group type: EXPERIMENTAL
Intervention: Recombinant human epidermal growth factor (rhEGF) with silver sulfadiazine (SD‐Ag)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Silver sulfadiazine (SD‐Ag)
Number of subjects: 80
Study: 18624588

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) - Individual format (CBT-I)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) - Group format (CBT-G)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT) - Individual format (IPT-I)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT) - Group format (IPT-G)
Number of subjects: 112
Study: 15691863

Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh) in type 2 diabetic patients
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) in type 2 diabetic patients
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: ACh/SNP ratio in type 2 diabetic patients
Number of subjects: 103

Group type: COMPARATOR
Intervention: ACh/SNP ratio in control subjects
Number of subjects: 103
Study: 12665638

Group type: COMPARATOR
Intervention: Standard letter recommending central bone density screening (DXA)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Extended letter outlining treatment strategies based on subsequent central DXA scan results
Number of subjects: 197

Group type: COMPARATOR
Intervention: Standard letter
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Extended letter
Number of subjects: 197

Group type: COMPARATOR
Intervention: Screening for T </= 1.0
Number of subjects: 197

Group type: COMPARATOR
Intervention: Before screening
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: After physicians received letters
Number of subjects: 197
Study: 10560596

Group type: EXPERIMENTAL
Intervention: Celecoxib 50 mg twice a day
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg twice a day
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice a day
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg twice a day
Number of subjects: 1003

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1003
Study: 8735396

Group type: EXPERIMENTAL
Intervention: 10% cocaine
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 4% lignocaine with adrenaline (1:1000)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Both agents
Number of subjects: 29
Study: 1879032

Group type: EXPERIMENTAL
Intervention: Therapeutic group (eleutherosides treatment)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (insulin and potassium chloride treatment)
Number of subjects: 57
Study: 6461243

Group type: EXPERIMENTAL
Intervention: 60 mg of ferrous sulphate
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 120 mg of ferrous sulphate
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 240 mg of ferrous sulphate
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 135
Study: 31100545

Group type: EXPERIMENTAL
Intervention: Strength training program (TG) with therabands®
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Callisthenic training program (MG)
Number of subjects: 77

Group type: COMPARATOR
Intervention: No physical exercise (Control Group - CG)
Number of subjects: 77
Study: 30081576

Group type: EXPERIMENTAL
Intervention: Low FODMAP Gluten-Free Diet (LF-GFD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Regular Gluten-Free Diet (R-GFD)
Number of subjects: 50
Study: 26603110

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of remifentanil (REM) at 0.05 μg/kg/min
Number of subjects: 62

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of remifentanil (REM)
Number of subjects: 62
Study: 24884504

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus docetaxel (GD)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Docetaxel (D)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: TIMP-1 positive tumors
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: TIMP-1 negative tumors
Number of subjects: 337
Study: 22994060

Group type: EXPERIMENTAL
Intervention: 2% procaine electrophoresis
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Mesotherapy with 2% procaine solution
Number of subjects: 95

Group type: COMPARATOR
Intervention: Procaine galvanization
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo (0.9% physiological solution)
Number of subjects: 95
Study: 20200964

Group type: EXPERIMENTAL
Intervention: 800 IU of cholecalciferol and 1000 mg of calcium (calcium carbonate)
Number of subjects: 3195

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 3195
Study: 18005834

Group type: EXPERIMENTAL
Intervention: Midpalatal implant
Number of subjects: 51

Group type: COMPARATOR
Intervention: Headgear
Number of subjects: 51
Study: 16223887

Group type: EXPERIMENTAL
Intervention: Model I (using THC)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Model II (using THCCOOH to THC ratio)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Combination of models I and II
Number of subjects: 38
Study: 12297390

Group type: EXPERIMENTAL
Intervention: TA-CIN vaccine (533 micro g dose)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TA-CIN vaccine (26, 128, 533 micro g doses)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10207661

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8652235

Group type: EXPERIMENTAL
Intervention: Lenograstim 0.5 micrograms/kg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Lenograstim 2 micrograms/kg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Lenograstim 5 micrograms/kg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Lenograstim 10 micrograms/kg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Lenograstim (0.5 and 2 micrograms/kg)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Lenograstim (5 micrograms/kg)
Number of subjects: 66
Study: 2190504

Group type: EXPERIMENTAL
Intervention: Preoperative acute normovolemic hemodilution (PANH)
Number of subjects: 15
Study: 6258838

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 30361270

Group type: EXPERIMENTAL
Intervention: Hypothermia initiated within 6 hours of symptom onset using surface cooling pads and cold saline, continued in the cath lab with endovascular cooling (target temperature: ≤35°C at time of reperfusion).
Number of subjects: 101

Group type: COMPARATOR
Intervention: Not cooled (control group).
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Hypothermia group.
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both groups.
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both groups (CMR follow-up).
Number of subjects: 101
Study: 28070985

Group type: EXPERIMENTAL
Intervention: Causal mediation analysis with covariate adjustment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Default maximum likelihood methods
Number of subjects: 0
Study: 25200570

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 2.5 mg twice daily
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg twice daily
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 23597838

Group type: EXPERIMENTAL
Intervention: Anode over the left frontal cortex/cathode over the right supraorbital area
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Anode over the left fronto-temporal cortex/cathode over the right supraorbital area
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Anode over the left fronto-temporal cortex/cathode over the right fronto-temporal cortex
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Anode over the left fronto-temporal cortex/big-size cathode over the right supraorbital area
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 90
Study: 21244422

Group type: EXPERIMENTAL
Intervention: Foster care intervention
Number of subjects: 103

Group type: COMPARATOR
Intervention: Institutional care (control)
Number of subjects: 103
Study: 19307440

Group type: EXPERIMENTAL
Intervention: Endovenous radiofrequency ablation (RFA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional and endovenous procedures
Number of subjects: 0
Study: 20302683

Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride nasal spray, 0.6% (OLO) + Fluticasone nasal spray, 50 micrograms (FNS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azelastine nasal spray, 0.1% (AZE) + Fluticasone nasal spray, 50 micrograms (FNS)
Number of subjects: 0
Study: 15602116

Group type: EXPERIMENTAL
Intervention: Tiagabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertraline alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertraline with cognitive behavioural therapy
Number of subjects: 0
Study: 12037733

Group type: EXPERIMENTAL
Intervention: Group I (untreated hyperthyroid GD patients)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Group II (treated euthyroid GD patients)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: All GD patients
Number of subjects: 44
Study: 10537240

Group type: EXPERIMENTAL
Intervention: Acupuncture and self-care education added to pharmaceutical treatment
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control groups (published data, age- and sex-matched group, and 211 patients with angina pectoris symptoms)
Number of subjects: 105
Study: 7491852

Group type: EXPERIMENTAL
Intervention: U technique (no-scalpel vas deferens holding forceps)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: U technique
Number of subjects: 82
Study: 2112882

Group type: EXPERIMENTAL
Intervention: Recombinant human alpha-interferon (4 million units per day, three times weekly for 16 weeks)
Number of subjects: 26
Study: 369300

Group type: EXPERIMENTAL
Intervention: Lithium medication (24 mval/day to 36 mval/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 12160159

Group type: EXPERIMENTAL
Intervention: Prophylactic brimonidine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (no brimonidine)
Number of subjects: 31
Study: 30428772

Group type: EXPERIMENTAL
Intervention: manualised short-term psychoanalytic child psychotherapy (mPCP)
Number of subjects: 32

Group type: COMPARATOR
Intervention: treatment as usual (TaU)
Number of subjects: 32
Study: 27267429

Group type: EXPERIMENTAL
Intervention: Bouillons fortified with FePP only
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bouillons fortified with FeSO4 only
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bouillons fortified with FeSO4+NaPP
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bouillons fortified with FePP+NaPP
Number of subjects: 24
Study: 24903467

Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl (20 mg once daily)
Number of subjects: 2185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2185
Study: 22144723

Group type: EXPERIMENTAL
Intervention: Interactive training (5 hours of study time)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Self-study (5 hours of study time)
Number of subjects: 100
Study: 20837942

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study: 18413111

Group type: EXPERIMENTAL
Intervention: SADBE sensitization doses (12.5, 25, 50, or 250 microg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Elicitation doses (0, 0.2, 2, 20, and 200 microg)
Number of subjects: 50
Study: 16103584

Group type: EXPERIMENTAL
Intervention: Chloroquine plus sulfadoxine‐pyrimethamine
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Amodiaquine plus sulfadoxine‐pyrimethamine
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Amodiaquine plus artesunate
Number of subjects: 3000
Study: 11817501

Group type: EXPERIMENTAL
Intervention: Trazodone 100 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 10220927

Group type: EXPERIMENTAL
Intervention: Ethanol (0.5 or 0.8 g/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7484026

Group type: EXPERIMENTAL
Intervention: Preoperative intake of clear fluids up to 2 hours before general anaesthesia
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study: 2126219

Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Fluvoxamine + Pimozide
Number of subjects: 1

Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 1

Group type: COMPARATOR
Intervention: Pimozide alone
Number of subjects: 1
Study: 760861

Group type: EXPERIMENTAL
Intervention: Daily chemotherapy with reinforcements every 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reinforcement therapy only every 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside and an anthracycline for remission induction
Number of subjects: 0
Study: 31756300

Group type: EXPERIMENTAL
Intervention: Custom-fitted footwear (Clarks® footwear)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 33
Study: 30866973

Group type: EXPERIMENTAL
Intervention: LOCI intervention
Number of subjects: 0
Study: 29963766

Group type: EXPERIMENTAL
Intervention: Behavioural insights (BI) reminders
Number of subjects: 8999

Group type: COMPARATOR
Intervention: Standard reminders (control)
Number of subjects: 8999

Group type: EXPERIMENTAL
Intervention: Primer plus BI reminders
Number of subjects: 8999

Group type: COMPARATOR
Intervention: Primer (control)
Number of subjects: 8999
Study: 27815950

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 25077418

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 (commercial-scale lots)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 (pooled commercial-scale lots)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Pilot-scale lot
Number of subjects: 160
Study: 22214885

Group type: EXPERIMENTAL
Intervention: Actions enabling benefit from misfortune (e.g., betting on stock decline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceptions of actor's wicked desires
Number of subjects: 0
Study: 20083921

Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilatory Assist (NAVA)
Number of subjects: 14
Study: 17284249

Group type: EXPERIMENTAL
Intervention: Sildenafil (25, 50, and 100 mg)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 16126118

Group type: EXPERIMENTAL
Intervention: Captopril and 120 mg diltiazem
Number of subjects: 36

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 36
Study: 11791949

Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Bupropion SR and Methylphenidate
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Drug treatment (Bupropion SR and Methylphenidate)
Number of subjects: 30
Study: 10408666

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (400 mg/day) for 60 days
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Zinc plus arginine supplementation (4 g/day) for 60 days
Number of subjects: 384

Group type: COMPARATOR
Intervention: Control group (vaccine only)
Number of subjects: 384
Study: 8055863

Group type: COMPARATOR
Intervention: Advice Only (AO)
Number of subjects: 1261

Group type: COMPARATOR
Intervention: Counseling Intervention (CI)
Number of subjects: 1261

Group type: COMPARATOR
Intervention: Counseling plus Nicotine-Containing Gum (CI + NCG)
Number of subjects: 1261
Study: 2568065

Group type: EXPERIMENTAL
Intervention: 600 micrograms of selenium alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 600 micrograms of selenium plus 600 IU of vitamin E
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31439007

Group type: EXPERIMENTAL
Intervention: Sensor-equipped insoles combined with photo documentation and smartphone application (Smart Prevent Diabetic Feet Application) for daily foot temperature measurements.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Education about regular foot care provided to both groups.
Number of subjects: 300
Study: 27937077

Group type: EXPERIMENTAL
Intervention: Royal Jelly (RJ) - 9 capsules (350 mg/capsule) per day for 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo - 9 capsules per day for 3 months
Number of subjects: 40
Study: 25275693

Group type: EXPERIMENTAL
Intervention: Vaginal insert containing 10 mg timed-release dinoprostone (PGE2)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Double-balloon catheter
Number of subjects: 52
Study: 22641110

Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic biliary stenting (PTBS)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Surgical bypass
Number of subjects: 142
Study: 21632072

Group type: COMPARATOR
Intervention: Exercise regimen (submaximal at 35% ± 5% or maximal oxygen consumption)
Number of subjects: 17
Study: 19497091

Group type: EXPERIMENTAL
Intervention: Acetylcysteine 1200 mg orally twice daily for two doses before and two doses after the procedure
Number of subjects: 2300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2300
Study: 16123767

Group type: EXPERIMENTAL
Intervention: 100 ng/ml ketamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15151264

Group type: EXPERIMENTAL
Intervention: Intravenous calcitriol pulse doses (2‐8 mcg/3x/week)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study: 11488772

Group type: EXPERIMENTAL
Intervention: Adrenomedullin (ADM) infusion (1-30 pmol x min(‐1))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Proadrenomedullin N‐terminal 20 peptide (PAMP) infusion (100-3000 pmol x min(‐1))
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Adrenomedullin (ADM) co-infused with NEP inhibitor thiorphan (30 nmol x min(‐1))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Adrenomedullin (ADM) co-infused with control vasoconstrictor noradrenaline (120 pmol x min(‐1))
Number of subjects: 8
Study: 9138439

Group type: EXPERIMENTAL
Intervention: Intravenous pentagastrin
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 8154874

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 3046645

Group type: EXPERIMENTAL
Intervention: Aspirin (330 mg three times a day) plus dipyridamole (75 mg three times a day) for a mean of 25 months, with warfarin for three months.
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo for a mean of 23 months, with warfarin for three months.
Number of subjects: 320
Study: 29805116

Group type: EXPERIMENTAL
Intervention: Elobixibat 10 mg/day for 2 weeks
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Elobixibat (varied doses: 5 mg/day, 10 mg/day, or 15 mg/day) for 52 weeks
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 133
Study: 28277886

Group type: EXPERIMENTAL
Intervention: Endometrin® 200 mg/day (Group A)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Endometrin® 300 mg/day (Group B)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Endometrin® 200 mg/day (control group)
Number of subjects: 146
Study: 26194656

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25 % (40 ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.25 % (40 ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Desflurane alone (Control group)
Number of subjects: 60
Study: 24281309

Group type: EXPERIMENTAL
Intervention: 1% pimecrolimus cream
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1% hydrocortisone cream
Number of subjects: 30
Study: 21923426

Group type: EXPERIMENTAL
Intervention: Formoterol 12 μg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Formoterol 24 μg
Number of subjects: 10
Study: 18662624

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery without cardiopulmonary bypass
Number of subjects: 66

Group type: COMPARATOR
Intervention: Coronary artery bypass graft surgery with cardiopulmonary bypass
Number of subjects: 66
Study: 16585121

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 400 microg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vaginal misoprostol 200 microg
Number of subjects: 60
Study: 12004271

Group type: EXPERIMENTAL
Intervention: Drugs with DLHigh
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Drugs with DLLow
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Each active drug with DLHigh
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Each active drug with DLLow
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: No drugs with IQ > median
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: One drug with IQ > median
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Two drugs with IQ > median
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Three drugs with IQ > median
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Four or five drugs with IQ > median
Number of subjects: 137
Study: 10213434

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Rocuronium 1.2 mg/kg
Number of subjects: 38
Study: 7605186

Group type: EXPERIMENTAL
Intervention: Intravenous orphenadrine citrate (60mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 2189123

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (0, 15, 30, or 60 mg daily for six months)
Number of subjects: 26